UNSPSC 51111627: Doxifluridine

This classification denotes a pyrimidine antagonist with the molecular formula C9H11FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1JK16Y2JP, chemically known as 1-((4s,2r,3r,5r)-3,4-dihydroxy-5-methyloxolan-2-yl)-5-fluoro-1,3-dihydropyrimidine-2,4-dione but generally known as doxifluridine, which bears US NIH Compound Identifier 18343. European Medicines Agency schedules Doxifluridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06389MIG.

UNSPSC 51111627 Doxifluridine (Commodity) covers procurement of doxifluridine, a fluoropyrimidine antineoplastic agent used in oncology treatment. State and local governments purchase this pharmaceutical primarily through health departments, correctional health services, and public hospital systems for inpatient and outpatient cancer care. Procurement typically occurs via standing supply contracts, group purchasing organization (GPO) agreements, or state pharmaceutical cooperative vehicles negotiated at the state level and adopted by subordinate jurisdictions. The issuing bodies are predominantly state health agencies, departments of corrections overseeing prison medical care, and municipal or county hospital authorities operating integrated oncology services.

The source provides no recent state and local contract opportunities tagged to this code. Without posted RFPs, RFQs, ITBs, or IFBs in the available record, the geographic distribution and current market activity cannot be characterized from recent solicitation data.